
Gain Therapeutics, Inc. (NASDAQ:GANX – Free Report) – Equities researchers at HC Wainwright raised their FY2026 earnings per share (EPS) estimates for shares of Gain Therapeutics in a research report issued on Thursday, November 12th. HC Wainwright analyst R. Selvaraju now expects that the company will post earnings of ($0.38) per share for the year, up from their prior forecast of ($0.49). HC Wainwright has a “Buy” rating and a $8.00 price target on the stock. The consensus estimate for Gain Therapeutics’ current full-year earnings is ($0.43) per share. HC Wainwright also issued estimates for Gain Therapeutics’ Q4 2026 earnings at ($0.07) EPS, Q1 2027 earnings at ($0.08) EPS, Q2 2027 earnings at ($0.08) EPS, Q3 2027 earnings at ($0.09) EPS, Q4 2027 earnings at ($0.09) EPS and FY2027 earnings at ($0.35) EPS.
Several other research firms have also commented on GANX. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Gain Therapeutics in a report on Friday, September 4th. BTIG Research reiterated a “buy” rating and issued a $5.00 target price on shares of Gain Therapeutics in a research report on Monday, October 5th. Four research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $7.67.
View Our Latest Stock Report on Gain Therapeutics
Gain Therapeutics Trading Down 9.6%
Shares of GANX opened at $0.94 on Monday. The firm has a market cap of $41.87 million, a price-to-earnings ratio of -2.24 and a beta of 0.29. The company has a debt-to-equity ratio of 0.02, a quick ratio of 4.36 and a current ratio of 5.36. Gain Therapeutics has a fifty-two week low of $0.94 and a fifty-two week high of $4.34. The firm has a 50 day moving average price of $1.45 and a 200-day moving average price of $1.81.
Gain Therapeutics (NASDAQ:GANX – Get Free Report) last issued its quarterly earnings results on Tuesday, November 10th. The company reported ($0.07) EPS for the quarter, beating analysts’ consensus estimates of ($0.12) by $0.05.
Hedge Funds Weigh In On Gain Therapeutics
Several institutional investors and hedge funds have recently bought and sold shares of GANX. Empowered Funds LLC bought a new stake in Gain Therapeutics in the third quarter valued at approximately $90,000. Hohimer Wealth Management LLC purchased a new stake in shares of Gain Therapeutics during the third quarter valued at approximately $571,000. StoneX Group Inc. bought a new position in shares of Gain Therapeutics in the third quarter worth approximately $44,000. BOKF NA bought a new position in shares of Gain Therapeutics in the third quarter worth approximately $35,000. Finally, Squarepoint Ops LLC bought a new position in shares of Gain Therapeutics in the second quarter worth approximately $277,000. 11.97% of the stock is currently owned by institutional investors.
About Gain Therapeutics
Gain Therapeutics, Inc. is a biotechnology company developing small-molecule treatments for neurological and other diseases linked to dysfunctional proteins. Its research focuses on conditions for which existing therapies may not address the underlying protein dysfunction. The company uses its discovery platform, which combines computational methods and structural biology, to identify previously unexplored binding sites on proteins. It aims to develop compounds that bind at these sites and help restore protein function.
Recommended Stories
- Five stocks we like better than Gain Therapeutics
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Gain Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gain Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
